Unraveling the genetics of systemic lupus erythematosus - PubMed (original) (raw)

Review

Unraveling the genetics of systemic lupus erythematosus

John B Harley et al. Springer Semin Immunopathol. 2006 Oct.

Abstract

The capacity to locate polymorphisms on a virtually complete map of the human genome coupled with the ability to accurately evaluate large numbers (by historical standards) of genetic markers has led to gene identification in complex diseases, such as systemic lupus erythematosus (SLE or lupus). While this is a phenotype with enormous clinical variation, the twin studies and the observed familial aggregation, along with the genetic effects now known, suggest a strong genetic component. Unlike type 1 diabetes, lupus genetics is not dominated by the powerful effect of a single locus. Instead, there are at least six known genetic association effects in lupus of smaller magnitude (odds ratio <2), and at least 17 robust linkages (established and arguably confirmed independently) defining potentially responsible genes that largely remain to be discovered. The more convincing genetic associations include the human leukocyte antigen region (with multiple genes), C1q, PTPN22, PDCD1, Fc receptor-like 3, FcgammaRIIA, FcgammaRIIIA, interferon regulatory factor 5, and others. How they contribute to disease risk remains yet to be clarified, beyond the obvious speculation derived from what has previously been learned about these genes. Certainly, they are expected to contribute to lupus risk independently and in combination with each other, with genes not yet identified, and with the environment. A substantial number of genes (>10) are expected to be identified to contribute to lupus or in its many subsets defined by clinical and laboratory features.

PubMed Disclaimer

Cited by

Evaluating the association of interleukin-10 gene promoter -592 A/C polymorphism with lupus nephritis susceptibility.
Abdallah E, Waked E, Abdelwahab MA. Abdallah E, et al. Kidney Res Clin Pract. 2016 Mar;35(1):29-34. doi: 10.1016/j.krcp.2015.11.002. Epub 2015 Dec 2. Kidney Res Clin Pract. 2016. PMID: 27069855 Free PMC article.
Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.
Liu LL, Jiang Y, Wang LN, Yao L, Li ZL. Liu LL, et al. Drugs. 2012 Jul 30;72(11):1521-33. doi: 10.2165/11635030-000000000-00000. Drugs. 2012. PMID: 22818016 Review.
The interferon-alpha signature of systemic lupus erythematosus.
Obermoser G, Pascual V. Obermoser G, et al. Lupus. 2010 Aug;19(9):1012-9. doi: 10.1177/0961203310371161. Lupus. 2010. PMID: 20693194 Free PMC article. Review.
Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients.
Salloum R, Franek BS, Kariuki SN, Rhee L, Mikolaitis RA, Jolly M, Utset TO, Niewold TB. Salloum R, et al. Arthritis Rheum. 2010 Feb;62(2):553-61. doi: 10.1002/art.27182. Arthritis Rheum. 2010. PMID: 20112359 Free PMC article.
Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study.
Sánchez E, Comeau ME, Freedman BI, Kelly JA, Kaufman KM, Langefeld CD, Brown EE, Alarcón GS, Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri M, Reveille JD, Vilá LM, Merrill JT, Tsao BP, Kamen DL, Gilkeson GS, James JA, Vyse TJ; International Consortium on the Genetics of Systemic Lupus Erythematosus; Gaffney PM, Jacob CO, Niewold TB, Richardson BC, Harley JB, Alarcón-Riquelme ME, Sawalha AH. Sánchez E, et al. Arthritis Rheum. 2011 Nov;63(11):3493-501. doi: 10.1002/art.30563. Arthritis Rheum. 2011. PMID: 21792837 Free PMC article.

References

1. Tissue Antigens. 1991 Jan;37(1):10-5 - PubMed
1. Tissue Antigens. 1997 Jun;49(6):635-9 - PubMed
1. Rheumatology (Oxford). 2005 Mar;44(3):287-92 - PubMed
1. Am J Hum Genet. 2004 Aug;75(2):330-7 - PubMed
1. Diabetes. 2004 Nov;53(11):3020-3 - PubMed

Unraveling the genetics of systemic lupus erythematosus - PubMed (original) (raw)